Pelthos Therapeutics (PTHS) Cash & Current Investments (2022 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Cash & Current Investments of $18.0 million for Q4 2025, up 3413.26% year-over-year from $513000.0 in Q4 2024, and up 26.01% quarter-over-quarter from $14.3 million in Q3 2025.
Pelthos Therapeutics (PTHS) Cash & Current Investments (2022 - 2026) Analysis & Trends
Pelthos Therapeutics' Cash & Current Investments history runs 4 years deep, the most recent figure standing at $18.0 million for Q4 2025.
- In Q4 2025, Cash & Current Investments rose 3413.26% year-over-year to $18.0 million; the TTM figure through Dec 2025 stood at $18.0 million (up 3413.26% YoY), while the FY2025 annual figure was $18.0 million, up 3413.26% from the prior year.
- Cash & Current Investments for Q4 2025 stood at $18.0 million, up from $14.3 million in the prior quarter.
- The five-year high for Cash & Current Investments was $18.0 million in Q4 2025, with the low at $22786.0 in Q3 2023.
- The 4-year median for Cash & Current Investments is $131317.0 (2025), against an average of $3.1 million.
- The sharpest annual moves came in 2024 and 2025: Cash & Current Investments surged 7656.4% in 2024, then tumbled 97.54% in 2025.
- Pelthos Therapeutics' Cash & Current Investments stood at $55074.0 in 2022, then surged by 74.31% to $96000.0 in 2023, then surged by 434.38% to $513000.0 in 2024, then soared by 3413.26% to $18.0 million in 2025.
- Business Quant data shows PTHS's Cash & Current Investments at $18.0 million in Q4 2025, $14.3 million in Q3 2025, and $59172.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | 24.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.56 Mn |
| Dec 31, 2025 | 18.02 Mn |
| Sep 30, 2025 | 14.30 Mn |
| Jun 30, 2025 | 59,172.00 |
| Mar 31, 2025 | 131,317.00 |
| Dec 31, 2024 | 513,000.00 |
| Sep 30, 2024 | 513,000.00 |
| Jun 30, 2024 | 2.41 Mn |
| Mar 31, 2024 | 3.77 Mn |
| Dec 31, 2023 | 96,000.00 |
| Sep 30, 2023 | 22,786.00 |
| Jun 30, 2023 | 81,893.00 |
| Mar 31, 2023 | 48,608.00 |
| Dec 31, 2022 | 55,074.00 |